Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00961532 · ClinicalTrials.gov registry record · Phase 2
Improving Platelet Activity for Cerebral Hemorrhage Treatment - DDAVP Proof of Concept
A Phase 2 study, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT00961532: Completed Phase 2 study, sponsored by Northwestern University.
NCT00961532 is a Phase 2 study that has completed, run by Northwestern University. The registered enrollment target is 14 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00961532, a Phase 2 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
The investigators intend to show that DDAVP improves platelet activity from baseline to 60 minutes after treatment start.
Primary Outcome
The Platelet Function Analyzer (PFA) is a commercially available point-of-care assay that measures the time to closure of an aperature. Longer time to closure indicates less platelet activity. EPI denotes epinephrine (as opposed to adenosine diphosphate) as the stimulant to platelet aggregation. In our laboratory, a time to closure of at least 172 seconds in consistent with an aspirin effect.
Interventions
- DRUG DDAVP injection (desmopressin acetate)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2010-12 |
| Est. Completion | 2013-12 |
| Phase | Phase 2 |
What the finished NCT00961532 record still lists
NCT00961532 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 1 intervention - of which DDAVP injection (desmopressin acetate) is the first listed.
NCT00961532 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00961532 about?
NCT00961532 is a clinical study titled "Improving Platelet Activity for Cerebral Hemorrhage Treatment - DDAVP Proof of Concept". The investigators intend to show that DDAVP improves platelet activity from baseline to 60 minutes after treatment start.
What is the current status of trial NCT00961532?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2010-12. Estimated completion is 2013-12.
What interventions are being tested in trial NCT00961532?
The interventions under investigation include: DDAVP injection (desmopressin acetate) (DRUG).
Who is sponsoring clinical trial NCT00961532?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00961532's enrollment target sits among peer trials
14 1941st of 2000 higher than 54 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia